MITI2: Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy
Last 5th of July, we took part in the kick-off meeting in Nantes of a R&D project lead by INSERM in which Beonchip will be participating in the next 4 years.
MITI2 focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which an unprecedented association with the clinical outcome of patients in various inflammatory diseases has already been shown, for therapeutic use in inflammatory bowel diseases (IBD).
Existing treatments are complex, with most people requiring lifelong medications, dietary and lifestyle modifications, and some requiring surgery. In this context, the development of new therapeutic approaches appears essential. Among these approaches, immunotherapy and cell-based therapy are particularly promising strategies.
MITI2 aims at providing a pre-clinical package including i) the proof of concept that a cellular immunotherapy using the identified Tregs subset represents a treatment for IBDs and ii) the reglementary pre-clinical in vitro and in vivo toxicity.
Project reference: HORIZON-HLTH-2022-DISEASE-06-02-two-stage/101080445
